NIAID doses first patient with Moderna’s variant specific COVID-19 vaccine candidate
The trial will evaluate the safety and immunogenicity of the…
The trial will evaluate the safety and immunogenicity of the mRNA-1273.351 vaccine candidate in 200 healthy adult volunteers.